查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1500198

非专利药注射剂市场：按产品、类型、应用、分销管道划分 - 2024-2030 年全球预测

Generic Injectables Market by Product (Large Molecule Injectables, Small Molecule Injectables), Type (Cytokines, Insulin, Monoclonal Antibodies), Application, Distribution Channel - Global Forecast 2024-2030
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计2023年非专利药市场规模为331.2亿美元，2024年达365.8亿美元，到2030年将达到672.2亿美元，预计复合年增长率为10.64%。

非专利药注射剂是透过注射给药的非品牌药物，具有与品牌药物相同的活性成分、规格、剂型、给药途径、品质、性能特征和预期用途。通常在原产品专利到期后出售。非专利药注射剂透过提供具有成本效益的品牌药物替代品，有助于节省医疗费用并为患者提供便利。对更实惠的药物的需求不断增长，以及由于几种品牌注射剂的专利到期而导致学名药进入市场，推动了非专利药注射剂市场的发展。世界各国政府的成本控制政策也支持普及具有成本效益的非专利药注射剂。此外，需要注射药物治疗的慢性疾病的增加也支持了市场的成长。儘管成长前景广阔，但市场在维持高品质标准方面面临挑战，如果管理不当，可能会导致召回和声誉受损。此外，市场竞争激烈且价格下降，这可能会阻碍非专利药注射剂的采用。然而，专注于先进药物输送系统、生物相似药开发、永续生产以及提高产品稳定性和保质期的配方进步为市场扩张提供了有利可图的机会。

主要市场统计
基准年[2023] 331.2亿美元
预计年份 [2024] 365.8亿美元
预测年份 [2030] 672.2亿美元
复合年增长率（%） 10.64%

区域洞察

美洲尤其是美国的非专利药注射剂市场正在经历显着成长。由于品牌药物的专利到期、政府努力最大限度地降低医疗成本以及慢性病的增加，该地区对负担得起的学名药的需求正在迅速增加。除了发达的医疗保健产业外，美洲地区也受惠于竞争激烈的市场格局，许多参与者不断努力推出新产品和具成本效益的製造流程。欧洲、中东和非洲 (EMEA) 地区的非专利药注射剂市场正在稳步成长。这一业绩是由旨在促进学名药使用和对生物相似药的重视的政府支持性卫生政策所推动的。虽然欧洲市场尤其受益于确保高品质产品的严格监管标准，但成本效益仍然是非专利药注射剂普及的驱动力。随着医疗基础设施的改善和药物取得的增加，中东和非洲的市场正在稳步发展。非专利药注射药领域目前在亚太（Asia-Pacific）地区正在迅速扩张。印度和中国因其庞大的人口基数、不断上涨的医疗成本以及政府对学名药生产的支持政策而成为这一增长的主要贡献者。该地区还拥有大量学名药生产商，支持了当地市场的成长。此外，慢性病盛行率的不断上升以及新兴国家加强医疗保健系统的共同努力，为亚太地区非专利药注射剂市场的成长奠定了坚实的基础。

FPNV定位矩阵

FPNV 定位矩阵对于评估供应商在非专利药注射剂市场的定位至关重要。此矩阵提供了对供应商的全面评估，并检查了与商务策略和产品满意度相关的关键指标。这种详细的评估使用户能够根据自己的要求做出明智的决定。根据评估结果，供应商被分为代表其成功程度的四个像限：前沿（F）、探路者（P）、利基（N）和重要（V）。

市场占有率分析

市场占有率分析是一种综合工具，可对非专利药注射剂市场供应商的现状进行深入而详细的评估。透过仔细比较和分析供应商的贡献，您可以更深入地了解每个供应商的绩效以及他们在争夺市场占有率时面临的挑战。这些贡献包括整体收益、客户群和其他重要指标。此外，该分析还提供了对该行业竞争力的宝贵见解，包括研究基准年期间观察到的累积、分散主导地位和合併特征等因素。有了这些详细信息，供应商可以做出更明智的决策并製定有效的策略，以在市场竞争中保持领先地位。

战略分析和建议

策略分析对于寻求在全球市场站稳脚跟的组织至关重要。对目前在非专利药注射剂市场中的地位进行全面评估，使公司能够做出符合其长期愿望的明智决策。此关键评估涉及对组织的资源、能力和整体绩效进行彻底分析，以确定核心优势和需要改进的领域。

目录

第一章 前言

第二章调查方法

第三章执行摘要

第四章市场概况

第五章市场洞察

  • 市场动态
    • 促进因素
      • 慢性病的流行和对具有成本效益的药物的需求
      • 专利到期增加并重视引进学名药
      • 政府对学名药和注射剂的有利核准
    • 抑制因素
      • 病人和医生对品牌药物的偏好
    • 机会
      • 正在进行的与非专利药注射药物相关的研究和开发活动
      • 非专利药注射剂製造的长期战略合作伙伴关係
    • 任务
      • 对注射品质和製造差异的担忧
  • 市场区隔分析
    • 产品：由于可用性和熟悉度，各个治疗领域小分子注射剂的消费量增加
    • 类型：在新的具有成本效益的治疗方法的研究和开发中对非专利细胞激素和单株抗体的需求持续增长
    • 应用：非专利药注射剂在心臟病学和肿瘤学领域的显着优势需要长期和永续的药物成本
    • 分销管道：网路商店因其便利性和有竞争力的价格而越来越受欢迎。
  • 市场扰动分析
  • 波特五力分析
  • 价值炼和关键路径分析
  • 价格分析
  • 技术分析
  • 专利分析
  • 贸易分析
  • 法规结构分析

第六章非专利药市场：副产品

  • 聚合物注射
  • 低分子注射液

第七章非专利药注射剂市场：按类型

  • 细胞激素
  • 胰岛素
  • 单株抗体
  • 疫苗

第八章非专利药注射剂市场：依应用分类

  • 心臟病学
  • 糖尿病
  • 免疫学
  • 肿瘤学

第九章非专利药注射剂市场：依通路

  • 医院药房
  • 网路处方笺店
  • 零售药房

第十章美洲非专利用仿製药市场

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美国

第十一章亚太地区非专利药注射剂市场

  • 澳洲
  • 中国
  • 印度
  • 印尼
  • 日本
  • 马来西亚
  • 菲律宾
  • 新加坡
  • 韩国
  • 台湾
  • 泰国
  • 越南

第十二章 欧洲、中东和非洲非专利药注射剂市场

  • 丹麦
  • 埃及
  • 芬兰
  • 法国
  • 德国
  • 以色列
  • 义大利
  • 荷兰
  • 奈及利亚
  • 挪威
  • 波兰
  • 卡达
  • 俄罗斯
  • 沙乌地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公国
  • 英国

第十三章竞争格局

  • 2023 年市场占有率分析
  • FPNV 定位矩阵，2023
  • 竞争情境分析
    • Gland Pharma 获得美国FDA核准注射非专利药
    • Meitheal Pharmaceuticals 宣布扩大非专利药注射剂产品组合
    • Endo 推出 Noxafil（泊沙康唑）注射液的首个非专利药
  • 战略分析和建议

第14章竞争产品组合

  • 主要企业简介
  • 主要产品系列
Product Code: MRR-C002B1C997E0

[180 Pages Report] The Generic Injectables Market size was estimated at USD 33.12 billion in 2023 and expected to reach USD 36.58 billion in 2024, at a CAGR 10.64% to reach USD 67.22 billion by 2030.

Generic injectables are non-branded pharmaceuticals that are administered by injection and have the same active ingredients, strength, dosage form, route of administration, quality, performance characteristics, and intended use as their branded counterparts. They are typically marketed after the original branded product's patent protection has expired. Generic injectables offer a cost-effective alternative to brand-name drugs, thereby contributing to healthcare savings and increased accessibility for patients. The generic injectables market is fueled by the increasing demand for more affordable pharmaceuticals and the expiration of patents for multiple branded injectables, which allows generic versions to enter the market. Cost-containment policies by governments worldwide also drive the uptake of cost-effective generic injectables. In addition, the rise in the prevalence of chronic diseases that require injectable drugs for treatment supports the market growth. Despite the promising growth, the market faces challenges due to maintaining high-quality standards, which, if not adequately managed, can lead to recalls and reputational damage. Furthermore, the market is subject to intense competition and price erosion, which can hinder the adoption of generic injectables. However, research focusing on advanced drug delivery systems, biosimilar development, sustainable production, and formulation advancements to improve product stability and storage presents lucrative opportunities for market expansion.

KEY MARKET STATISTICS
Base Year [2023] USD 33.12 billion
Estimated Year [2024] USD 36.58 billion
Forecast Year [2030] USD 67.22 billion
CAGR (%) 10.64%

Regional Insights

The market for generic injectables in the Americas, and particularly in the United States, has seen significant growth. The expiration of patents for branded drugs, government initiatives to minimize healthcare costs, and the rising prevalence of chronic diseases have resulted in a surging need for affordable generic alternatives in this region. The Americas region benefits from a well-developed healthcare sector and a competitive market landscape where numerous players are constantly engaged in the introduction of new products and cost-effective manufacturing processes. The Europe, Middle East, and Africa (EMEA) region has experienced steady growth in the generic injectables market. This performance is facilitated by supportive governmental health policies aimed at promoting the use of generics, as well as an emphasis on biosimilars. The European market, in particular, benefits from stringent regulatory standards that ensure high-quality products, while cost-effectiveness remains a driving factor behind the widespread adoption of generic injectables. In the Middle East and Africa, the market is steadily evolving with the improving healthcare infrastructure and increased accessibility to medication. The Asia-Pacific (APAC) region is currently witnessing rapid expansion in the generic injectables sector. India and China, with their vast population base, increasing healthcare expenditure, and supportive government policies for generic medicine production, are contributing significantly to this growth. The region also hosts a significant number of generic drug manufacturers, which bolster the local market growth. Additionally, the growing incidence of chronic conditions, coupled with a concerted effort to enhance healthcare systems in emerging economies, provides a robust platform for the growth of the generic injectables market in APAC.

Market Insights

  • Market Dynamics

The market dynamics represent an ever-changing landscape of the Generic Injectables Market by providing actionable insights into factors, including supply and demand levels. Accounting for these factors helps design strategies, make investments, and formulate developments to capitalize on future opportunities. In addition, these factors assist in avoiding potential pitfalls related to political, geographical, technical, social, and economic conditions, highlighting consumer behaviors and influencing manufacturing costs and purchasing decisions.

    • Market Drivers
      • Prevalence of chronic diseases and need for cost-effective medications
      • Increasing patent expirations and emphasis on adopting generic drugs
      • Favorable government approvals for generic drugs & injectables
    • Market Restraints
      • Preference for branded drugs by patients and physicians
    • Market Opportunities
      • Ongoing R&D activities associated with generic injectable drugs
      • Strategic long-term partnerships to manufacture generic injectables
    • Market Challenges
      • Concerns associated with injectable quality and manufacturing variability
  • Market Segmentation Analysis
    • Product: Growing consumption of small molecule injectables in various therapeutic areas owing to their accessibility and familiarity
    • Type: Demand for generic cytokines and monoclonal antibodies in ongoing R&D for cost-effective novel therapies
    • Application: Significant benefits of generic injectables in cardiology and oncology, requiring long-term and sustainable medication costs
    • Distribution Channel: Inclining preferences for online stores offering convenience and competitive pricing
  • Market Disruption Analysis
  • Porter's Five Forces Analysis
  • Value Chain & Critical Path Analysis
  • Pricing Analysis
  • Technology Analysis
  • Patent Analysis
  • Trade Analysis
  • Regulatory Framework Analysis

FPNV Positioning Matrix

The FPNV positioning matrix is essential in evaluating the market positioning of the vendors in the Generic Injectables Market. This matrix offers a comprehensive assessment of vendors, examining critical metrics related to business strategy and product satisfaction. This in-depth assessment empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success, namely Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The market share analysis is a comprehensive tool that provides an insightful and in-depth assessment of the current state of vendors in the Generic Injectables Market. By meticulously comparing and analyzing vendor contributions, companies are offered a greater understanding of their performance and the challenges they face when competing for market share. These contributions include overall revenue, customer base, and other vital metrics. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With these illustrative details, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Recent Developments

Gland Pharma gets USFDA nod for generic injectable

Gland Pharma announced its approval from the US FDA to market its generic version of Angiotensin II Injection, presented in a 2.5 mg/mL single-dose vial. The company's advancements underscore its commitment to enhancing its portfolio in the generic injectables market, ensuring the availability of essential medications within the healthcare system. [Published On: 2023-11-15]

Meitheal Pharmaceuticals Announces Expansion of Portfolio of Generic Injectable Products

Meitheal Pharmaceuticals, Inc., part of the fully integrated generic injectables field, has significantly broadened its market offerings through a recent deal orchestrated by Hong Kong King-Friend Industry Co., Ltd. (HKF), their parent entity. The asset purchase agreement detailed by the two organizations leads to an impressive uptick in Meitheal's generic injectable repertoire. [Published On: 2023-10-04]

Endo Launches First Generic Version of Noxafil (posaconazole) Injection

Endo International plc's subsidiary Par Sterile Products has launched the U.S. market's inaugural generic form of Merck's Noxafil with its posaconazole injection (18 mg/mL), following the U.S. Food and Drug Administration's approval of their Abbreviated New Drug Application. This is a significant milestone for Endo, highlighting its commitment to expanding treatment options for healthcare professionals, enhancing its offerings, and affirming its status as a dependable provider of quality pharmaceuticals. [Published On: 2023-06-29]

Strategy Analysis & Recommendation

The strategic analysis is essential for organizations seeking a solid foothold in the global marketplace. Companies are better positioned to make informed decisions that align with their long-term aspirations by thoroughly evaluating their current standing in the Generic Injectables Market. This critical assessment involves a thorough analysis of the organization's resources, capabilities, and overall performance to identify its core strengths and areas for improvement.

Key Company Profiles

The report delves into recent significant developments in the Generic Injectables Market, highlighting leading vendors and their innovative profiles. These include Amgen Inc., AstraZeneca PLC, Aurobindo Pharma Limited, Baxter International Inc., Biocon Limited, Biological E. Limited, Bristol-Myers Squibb Company, Cipla Limited, Dr. Reddy's Laboratories Ltd., Endo International PLC, Eugia US LLC, Fresenius Kabi AG, Gland Pharma Limited by Shanghai Fosun Pharmaceutical Co., Ltd., GlaxoSmithKline PLC, Hikma Pharmaceuticals PLC, Johnson & Johnson Services, Inc., Lupin Limited, Meitheal Pharmaceuticals, Inc., Merck & Co. Inc., Novartis AG, Novo Nordisk A/S, Pfizer Inc., Samsung Biologics Co., Ltd., Sanofi S.A., Somerset Pharma, LLC, Sun Pharmaceutical Industries Ltd., Teva Pharmaceutical Industries Ltd., and Viatris Inc..

Market Segmentation & Coverage

This research report categorizes the Generic Injectables Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Product
    • Large Molecule Injectables
    • Small Molecule Injectables
  • Type
    • Cytokines
    • Insulin
    • Monoclonal Antibodies
    • Vaccines
  • Application
    • Cardiology
    • Diabetes
    • Immunology
    • Oncology
  • Distribution Channel
    • Hospital Pharmacy
    • Online Prescription Stores
    • Retail Pharmacy
  • Region
    • Americas
      • Argentina
      • Brazil
      • Canada
      • Mexico
      • United States
        • California
        • Florida
        • Illinois
        • New York
        • Ohio
        • Pennsylvania
        • Texas
    • Asia-Pacific
      • Australia
      • China
      • India
      • Indonesia
      • Japan
      • Malaysia
      • Philippines
      • Singapore
      • South Korea
      • Taiwan
      • Thailand
      • Vietnam
    • Europe, Middle East & Africa
      • Denmark
      • Egypt
      • Finland
      • France
      • Germany
      • Israel
      • Italy
      • Netherlands
      • Nigeria
      • Norway
      • Poland
      • Qatar
      • Russia
      • Saudi Arabia
      • South Africa
      • Spain
      • Sweden
      • Switzerland
      • Turkey
      • United Arab Emirates
      • United Kingdom

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Prevalence of chronic diseases and need for cost-effective medications
      • 5.1.1.2. Increasing patent expirations and emphasis on adopting generic drugs
      • 5.1.1.3. Favorable government approvals for generic drugs & injectables
    • 5.1.2. Restraints
      • 5.1.2.1. Preference for branded drugs by patients and physicians
    • 5.1.3. Opportunities
      • 5.1.3.1. Ongoing R&D activities associated with generic injectable drugs
      • 5.1.3.2. Strategic long-term partnerships to manufacture generic injectables
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with injectable quality and manufacturing variability
  • 5.2. Market Segmentation Analysis
    • 5.2.1. Product: Growing consumption of small molecule injectables in various therapeutic areas owing to their accessibility and familiarity
    • 5.2.2. Type: Demand for generic cytokines and monoclonal antibodies in ongoing R&D for cost-effective novel therapies
    • 5.2.3. Application: Significant benefits of generic injectables in cardiology and oncology, requiring long-term and sustainable medication costs
    • 5.2.4. Distribution Channel: Inclining preferences for online stores offering convenience and competitive pricing
  • 5.3. Market Disruption Analysis
  • 5.4. Porter's Five Forces Analysis
    • 5.4.1. Threat of New Entrants
    • 5.4.2. Threat of Substitutes
    • 5.4.3. Bargaining Power of Customers
    • 5.4.4. Bargaining Power of Suppliers
    • 5.4.5. Industry Rivalry
  • 5.5. Value Chain & Critical Path Analysis
  • 5.6. Pricing Analysis
  • 5.7. Technology Analysis
  • 5.8. Patent Analysis
  • 5.9. Trade Analysis
  • 5.10. Regulatory Framework Analysis

6. Generic Injectables Market, by Product

  • 6.1. Introduction
  • 6.2. Large Molecule Injectables
  • 6.3. Small Molecule Injectables

7. Generic Injectables Market, by Type

  • 7.1. Introduction
  • 7.2. Cytokines
  • 7.3. Insulin
  • 7.4. Monoclonal Antibodies
  • 7.5. Vaccines

8. Generic Injectables Market, by Application

  • 8.1. Introduction
  • 8.2. Cardiology
  • 8.3. Diabetes
  • 8.4. Immunology
  • 8.5. Oncology

9. Generic Injectables Market, by Distribution Channel

  • 9.1. Introduction
  • 9.2. Hospital Pharmacy
  • 9.3. Online Prescription Stores
  • 9.4. Retail Pharmacy

10. Americas Generic Injectables Market

  • 10.1. Introduction
  • 10.2. Argentina
  • 10.3. Brazil
  • 10.4. Canada
  • 10.5. Mexico
  • 10.6. United States

11. Asia-Pacific Generic Injectables Market

  • 11.1. Introduction
  • 11.2. Australia
  • 11.3. China
  • 11.4. India
  • 11.5. Indonesia
  • 11.6. Japan
  • 11.7. Malaysia
  • 11.8. Philippines
  • 11.9. Singapore
  • 11.10. South Korea
  • 11.11. Taiwan
  • 11.12. Thailand
  • 11.13. Vietnam

12. Europe, Middle East & Africa Generic Injectables Market

  • 12.1. Introduction
  • 12.2. Denmark
  • 12.3. Egypt
  • 12.4. Finland
  • 12.5. France
  • 12.6. Germany
  • 12.7. Israel
  • 12.8. Italy
  • 12.9. Netherlands
  • 12.10. Nigeria
  • 12.11. Norway
  • 12.12. Poland
  • 12.13. Qatar
  • 12.14. Russia
  • 12.15. Saudi Arabia
  • 12.16. South Africa
  • 12.17. Spain
  • 12.18. Sweden
  • 12.19. Switzerland
  • 12.20. Turkey
  • 12.21. United Arab Emirates
  • 12.22. United Kingdom

13. Competitive Landscape

  • 13.1. Market Share Analysis, 2023
  • 13.2. FPNV Positioning Matrix, 2023
  • 13.3. Competitive Scenario Analysis
    • 13.3.1. Gland Pharma gets USFDA nod for generic injectable
    • 13.3.2. Meitheal Pharmaceuticals Announces Expansion of Portfolio of Generic Injectable Products
    • 13.3.3. Endo Launches First Generic Version of Noxafil (posaconazole) Injection
  • 13.4. Strategy Analysis & Recommendation

14. Competitive Portfolio

  • 14.1. Key Company Profiles
  • 14.2. Key Product Portfolio

LIST OF FIGURES

  • FIGURE 1. GENERIC INJECTABLES MARKET RESEARCH PROCESS
  • FIGURE 2. GENERIC INJECTABLES MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL GENERIC INJECTABLES MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY REGION, 2023 VS 2030 (%)
  • FIGURE 5. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GENERIC INJECTABLES MARKET DYNAMICS
  • FIGURE 7. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2023 VS 2030 (%)
  • FIGURE 8. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 9. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
  • FIGURE 10. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 11. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 12. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 13. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
  • FIGURE 14. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 15. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 16. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 17. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 18. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 19. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 20. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 21. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 22. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 23. GENERIC INJECTABLES MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 24. GENERIC INJECTABLES MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. GENERIC INJECTABLES MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL GENERIC INJECTABLES MARKET SIZE, 2018-2023 (USD MILLION)
  • TABLE 4. GLOBAL GENERIC INJECTABLES MARKET SIZE, 2024-2030 (USD MILLION)
  • TABLE 5. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 6. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 7. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 8. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 9. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY LARGE MOLECULE INJECTABLES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 10. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY LARGE MOLECULE INJECTABLES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 11. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY SMALL MOLECULE INJECTABLES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 12. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY SMALL MOLECULE INJECTABLES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 13. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 14. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 15. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CYTOKINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 16. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CYTOKINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 17. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY INSULIN, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 18. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY INSULIN, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 19. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 20. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY MONOCLONAL ANTIBODIES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 21. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY VACCINES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 22. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY VACCINES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 23. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 24. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 25. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 26. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY CARDIOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 27. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DIABETES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 28. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DIABETES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 29. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 30. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 31. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 32. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ONCOLOGY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 33. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 34. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 35. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 36. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY HOSPITAL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 37. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ONLINE PRESCRIPTION STORES, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 38. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY ONLINE PRESCRIPTION STORES, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 39. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2018-2023 (USD MILLION)
  • TABLE 40. GLOBAL GENERIC INJECTABLES MARKET SIZE, BY RETAIL PHARMACY, BY REGION, 2024-2030 (USD MILLION)
  • TABLE 41. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 42. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 43. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 44. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 45. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 46. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 47. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 48. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 49. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 50. AMERICAS GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 51. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 52. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 53. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 54. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 55. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 56. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 57. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 58. ARGENTINA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 59. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 60. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 61. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 62. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 63. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 64. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 65. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 66. BRAZIL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 67. CANADA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 68. CANADA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 69. CANADA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 70. CANADA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 71. CANADA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 72. CANADA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 73. CANADA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 74. CANADA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 75. MEXICO GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 76. MEXICO GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 77. MEXICO GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 78. MEXICO GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 79. MEXICO GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 80. MEXICO GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 81. MEXICO GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 82. MEXICO GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 83. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 84. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 85. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 86. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 87. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 88. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 89. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 90. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 91. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY STATE, 2018-2023 (USD MILLION)
  • TABLE 92. UNITED STATES GENERIC INJECTABLES MARKET SIZE, BY STATE, 2024-2030 (USD MILLION)
  • TABLE 93. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 94. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 95. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 96. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 97. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 98. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 99. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 100. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 103. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 104. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 105. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 106. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 107. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 108. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 109. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 110. AUSTRALIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 111. CHINA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 112. CHINA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 113. CHINA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 114. CHINA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 115. CHINA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 116. CHINA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 117. CHINA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 118. CHINA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 119. INDIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 120. INDIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 121. INDIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 122. INDIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 123. INDIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 124. INDIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 125. INDIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 126. INDIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 127. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 128. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 129. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 130. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 131. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 132. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 133. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 134. INDONESIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 135. JAPAN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 136. JAPAN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 137. JAPAN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 138. JAPAN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 139. JAPAN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 140. JAPAN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 141. JAPAN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 142. JAPAN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 143. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 144. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 145. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 146. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 147. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 148. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 149. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 150. MALAYSIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 151. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 152. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 153. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 154. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 155. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 156. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 157. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 158. PHILIPPINES GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 159. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 160. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 161. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 162. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 163. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 164. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 165. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 166. SINGAPORE GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 167. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 168. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 169. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 170. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 171. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 172. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 173. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 174. SOUTH KOREA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 175. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 176. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 177. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 178. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 179. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 180. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 181. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 182. TAIWAN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 183. THAILAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 184. THAILAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 185. THAILAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 186. THAILAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 187. THAILAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 188. THAILAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 189. THAILAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 190. THAILAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 191. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 192. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 193. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 194. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 195. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 196. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 197. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 198. VIETNAM GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 199. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 200. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 201. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 202. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 203. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 204. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 205. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 206. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 207. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2018-2023 (USD MILLION)
  • TABLE 208. EUROPE, MIDDLE EAST & AFRICA GENERIC INJECTABLES MARKET SIZE, BY COUNTRY, 2024-2030 (USD MILLION)
  • TABLE 209. DENMARK GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 210. DENMARK GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 211. DENMARK GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 212. DENMARK GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 213. DENMARK GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 214. DENMARK GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 215. DENMARK GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 216. DENMARK GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 217. EGYPT GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 218. EGYPT GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 219. EGYPT GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 220. EGYPT GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 221. EGYPT GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 222. EGYPT GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 223. EGYPT GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 224. EGYPT GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 225. FINLAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 226. FINLAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 227. FINLAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 228. FINLAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 229. FINLAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 230. FINLAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 231. FINLAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 232. FINLAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 233. FRANCE GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 234. FRANCE GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 235. FRANCE GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 236. FRANCE GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 237. FRANCE GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 238. FRANCE GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 239. FRANCE GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 240. FRANCE GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 241. GERMANY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 242. GERMANY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 243. GERMANY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 244. GERMANY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 245. GERMANY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 246. GERMANY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 247. GERMANY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 248. GERMANY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 249. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 250. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 251. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 252. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 253. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 254. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 255. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 256. ISRAEL GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 257. ITALY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 258. ITALY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 259. ITALY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 260. ITALY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 261. ITALY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 262. ITALY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 263. ITALY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 264. ITALY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 265. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 266. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 267. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 268. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 269. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 270. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 271. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 272. NETHERLANDS GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 273. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 274. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 275. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 276. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 277. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 278. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 279. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 280. NIGERIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 281. NORWAY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 282. NORWAY GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 283. NORWAY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 284. NORWAY GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 285. NORWAY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 286. NORWAY GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 287. NORWAY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 288. NORWAY GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 289. POLAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 290. POLAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 291. POLAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 292. POLAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 293. POLAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 294. POLAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 295. POLAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 296. POLAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 297. QATAR GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 298. QATAR GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 299. QATAR GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 300. QATAR GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 301. QATAR GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 302. QATAR GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 303. QATAR GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 304. QATAR GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 305. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 306. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 307. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 308. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 309. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 310. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 311. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 312. RUSSIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 313. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 314. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 315. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 316. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 317. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 318. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 319. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 320. SAUDI ARABIA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 321. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 322. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 323. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 324. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 325. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 326. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 327. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 328. SOUTH AFRICA GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 329. SPAIN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 330. SPAIN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 331. SPAIN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 332. SPAIN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 333. SPAIN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 334. SPAIN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 335. SPAIN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 336. SPAIN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 337. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 338. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 339. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 340. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 341. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 342. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 343. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 344. SWEDEN GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 345. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2018-2023 (USD MILLION)
  • TABLE 346. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY PRODUCT, 2024-2030 (USD MILLION)
  • TABLE 347. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2018-2023 (USD MILLION)
  • TABLE 348. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY TYPE, 2024-2030 (USD MILLION)
  • TABLE 349. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2018-2023 (USD MILLION)
  • TABLE 350. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY APPLICATION, 2024-2030 (USD MILLION)
  • TABLE 351. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2023 (USD MILLION)
  • TABLE 352. SWITZERLAND GENERIC INJECTABLES MARKET SIZE, BY DISTRIBUTION CHANNEL, 2024-2030 (USD MILLION)
  • TABLE 353. TURKEY